Navigation Links
Statins reduce deaths from infection and respiratory illness, 8 years on from trial
Date:8/28/2011

The death rate among patients prescribed a statin in a major trial that ended in 2003 is still lower than those given a placebo, even though most participants in both groups have been taking statins ever since. ASCOT, the Anglo-Scandinavian Cardiac Outcomes Trial, was stopped early because the statin was so effective at preventing heart attacks and strokes, but a new analysis has shown that eight years on, the most significant difference between the groups is a reduction in deaths from infection and respiratory illness.

The latest findings, from researchers at Imperial College London, were presented at the European Society of Cardiology Congress in Paris today and simultaneously published in the European Heart Journal.

In the lipid-lowering arm of the trial, over 10,000 patients in the UK, Ireland and Scandinavia with high blood pressure were randomly allocated either atorvastatin or placebo between 1998 and 2000. In 2003, the trial was stopped early because the statin proved to be highly beneficial in preventing heart attacks and strokes. Since then, most participants from both groups have been taking statins.

The new analysis looked at the number and cause of deaths among the 4,605 participants in the ASCOT trial who are based in the UK. After 11 years' follow-up, overall mortality is 14 per cent lower in the group originally assigned atorvastatin, due largely to fewer deaths from infection and respiratory illness.

"This result is very unexpected," said Professor Peter Sever, from the International Centre for Circulatory Health at Imperial College London, who led the study. "The benefits of statins for preventing heart attacks and strokes are well-established, but after long-term follow-up the most significant effects seem to be on deaths from other causes. It's quite remarkable that there is still this difference between the two groups, eight years after the trial finished.

"Some studies have suggested that statins protect people against death from infectious diseases such as pneumonia. More research is needed to explain how these drugs might have unforeseen actions that prevent deaths from other illnesses."

Amongst UK participants, in the 11 years since the trial began, 460 of the original statin group have died, compared with 520 of the placebo group. The difference is largely explained by a 36 per cent reduction in deaths from infection and respiratory illness. Deaths from cardiovascular disease were also lower in the original statin group, but the difference was not statistically significant. There was no difference in deaths from cancer.

The initial results of the ASCOT lipid arm had a major influence on subsequent guidelines recommending the use of statins for people at risk of heart disease, including those produced by NICE in the UK. Another arm of the trial comparing different combinations of blood pressure-lowering drugs also had an important impact on clinical practice.


'/>"/>

Contact: Sam Wong
sam.wong@imperial.ac.uk
44-020-759-42198
Imperial College London
Source:Eurekalert

Related medicine news :

1. Statins May Benefit Prostate Cancer Patients
2. Alternative to Statins Shows Promise
3. Statins may slow progression of multiple sclerosis, new study finds
4. Statins May Slow Progression of Multiple Sclerosis, New Study Finds
5. Do Statins Lower Male Sex Drive?
6. Statins Wont Lower Colon Cancer Risk
7. Statins decrease risk of clot-related diseases
8. Some statins have unintended effects and warrant closer monitoring, study finds
9. Too Many Stroke Patients Go Without Statins
10. MSU team studies connection between statins, tendon ruptures
11. Statins associated with lower cancer recurrence following prostatectomy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2017)... ... June 22, 2017 , ... United Benefit ... welcome Whipple & Company as its newest Partner Firm. Headquartered in Coconut Creek, ... clients’ risk while tailoring optimized benefit packages that strengthen the relationship between employer ...
(Date:6/22/2017)... ... June 22, 2017 , ... Children’s National ... Heart Association (AHA) to launch a Rheumatic Heart Disease Center, with the goal ... of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries and low-income communities ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... environmental excellence. Maryland Recycling Network has awarded the Baltimore VA Medical Center, a ... Government Program Award for its efforts to promote waste reduction and promote recycling. ...
(Date:6/22/2017)... ... ... A June 12 article in The Star offers the advice ... oral hygiene by an aged parent who had recently suffered a series of minor ... steps, including scheduling a dentist visit. Northridge Dental Works, a Los Angeles Area dental ...
(Date:6/20/2017)... Murfreesboro, Tennessee (PRWEB) , ... June 20, 2017 ... ... chronic care services, announced today that Claritas Capital, a Nashville-based private equity firm, ... to accelerate our expansion plans for some time, and Claritas Capital offers the ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... 2017 Therapix Biosciences Ltd. (Nasdaq: TRPX), ... the development of cannabinoid-based drugs, today announced that ... at three upcoming scientific and investor conferences in ... Invitational: ...                     Wednesday, June ...
(Date:5/26/2017)... , May 26, 2017  Endo International plc (NASDAQ: ... President and CEO, will represent the Company in a fireside ... Conference on Tuesday, June 13, 2017 at 10:40 a.m. PT ... Terranea Resort in Rancho Palos Verdes, CA. ... the event will be available on the Company,s website at ...
(Date:5/24/2017)... , May 24, 2017  ivWatch LLC ... Equipment Manufacturer (OEM) Board to enable seamless integration ... patient monitoring systems, infusion pumps and other devices. ... will be able to help health care customers ... reduced risks related to IV therapy. ...
Breaking Medicine Technology: